BGLC vs NEM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The Advanced Deterministic Scorecard reveals a critically weak financial health with a Piotroski F-Score of 0/9, indicating severe deterioration in fundamental performance. Despite a low Price/Book and Price/Sales ratio suggesting potential value, the company is unprofitable with negative margins, declining revenue, and a disastrous five-year return of -98.9%. Strong liquidity ratios are overshadowed by an inability to generate profits or positive cash flow, while insider sentiment is neutral at best. The absence of Altman Z-Score and Graham Number prevents definitive valuation anchoring, but overwhelming evidence points to operational distress and high investment risk.
NEM shows bullish fundamentals based on deterministic rules. Financial strength is stable (F-Score 4/9). Key strengths include strong valuation and growth metrics. Price trades at a 155.7% premium to fair value estimate ($44.73), limiting near-term upside from a valuation perspective.
Compare Another Pair
Related Comparisons
BGLC vs NEM: Head-to-Head Comparison
This page compares BioNexus Gene Lab Corp. (BGLC) and Newmont Corporation (NEM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.